GCG and diabetes mellitus: Semaglutide is a novel glucagon-like peptide-1 (GLP-1, a 29-amino-acid-residue incretin hormone) receptor agonist with 94% homology, approved by the Food and Drug Administration for the treatment of diabetes in December 2017.